Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients

Psychiatry Research

Volumn 200, Issue 2-3, 2012, Pages 126-132

  Zhang, Jie ^a,b   Abdallah, Chadi G ^b   Wang, Junqing ^a   Wan, Xiaona ^a   Liang, Chunlian ^a   Jiang, Liyun ^a   Liu, Yuzhen ^c   Huang, Haixing ^c   Hong, Xiaohong ^a   Huang, Qingjun ^a   Wu, Renhua ^c   Xu, Chongtao ^a  

^a SHANDONG MENTAL HEALTH CENTER   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Adenosine; Antipsychotic; Schizophrenia; Sensory gating

Indexed keywords

ADENOSINE A2A RECEPTOR; ARIPIPRAZOLE; MESSENGER RNA; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADENOSINE A2A RECEPTOR GENE; ADULT; AMPLITUDE MODULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENCY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LATENT PERIOD; MALE; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY GATING; TREATMENT DURATION; UPREGULATION;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AUDITORY CORTEX; BENZODIAZEPINES; DIBENZOTHIAZEPINES; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; PIPERAZINES; QUINOLONES; REACTION TIME; RECEPTOR, ADENOSINE A2A; RISPERIDONE; SCHIZOPHRENIA; SENSORY GATING; UP-REGULATION;

EID: 84872370288     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.04.021     Document Type: Article

References (68)

1. Adler L.E., Waldo M.C. Counterpoint: a sensory gating-hippocampal model of schizophrenia. Schizophrenia Bulletin 1991, 17:19-24.
2. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry 1993, 150:1856-1861.
3. Adler L.E., Freedman R., Ross R.G., Olincy A., Waldo M.C. Elementary phenotypes in the neurobiological and genetic study of schizophrenia. Biological Psychiatry 1999, 46:8-18.
4. Adler L.E., Olincy A., Cawthra E.M., McRae K.A., Harris J.G., Nagamoto H.T., Waldo M.C., Hall M.H., Bowles A., Woodward L., Ross R.G., Freedman R. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. American Journal of Psychiatry 2004, 161:1822-1828.
5. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bulletin 1998, 24:189-202.
6. Akhondzadeh S., Shasavand E., Jamilian H., Shabestari O., Kamalipour A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. Journal of Clinical Pharmacy and Therapeutics 2000, 25:131-137.
7. Back S.A., Craig A., Luo N.L., Ren J., Akundi R.S., Ribeiro I., Rivkees S.A. Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Annals of Neurology 2006, 60:696-705.
8. Boison D., Singer P., Shen H.Y., Feldon J., Yee B.K. Adenosine hypothesis of schizophrenia - Opportunities for pharmacotherapy. Neuropharmacology 2011, 62:1527-1543.
9. Boutros N.N., Korzyukov O., Jansen B., Feingold A., Bell M. Sensory gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients. Psychiatry Research 2004, 126:203-215.
10. Bramon E., Rabe-Hesketh S., Sham P., Murray R.M., Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophrenia Research 2004, 70:315-329.
11. Brockhaus-Dumke A., Schultze-Lutter F., Mueller R., Tendolkar I., Bechdolf A., Pukrop R., Klosterkoetter J., Ruhrmann S. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biological Psychiatry 2008, 64:376-384.
12. Brundege J.M., Dunwiddie T.V. Role of adenosine as a modulator of synaptic activity in the central nervous system. Advances in Pharmacology 1997, 39:353-391.
13. Brunstein M.G., Belmonte-de-Abreu P., Souza D.O., Lara D.R. Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactions. Journal of Clinical Pharmacy and Therapeutics 2001, 26:155-156.
14. Bugert P., Dugrillon A., Gunaydin A., Eichler H., Kluter H. Messenger RNA profiling of human platelets by microarray hybridization. Journal of Thrombosis and Haemostasis 2003, 90:738-748.
15. Cunha R.A. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochemistry International 2001, 38:107-125.
16. de Wilde O.M., Bour L.J., Dingemans P.M., Koelman J.H., Linszen D.H. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophrenia Research 2007, 97:137-151.
17. De Freitas B., Schwartz G. Effects of caffeine in chronic psychiatric patients. American Journal of Psychiatry 1979, 136:1337-1338.
18. Deckert J., Brenner M., Durany N., Zochling R., Paulus W., Ransmayr G., Tatschner T., Danielczyk W., Jellinger K., Riederer P. Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport 2003, 14:313-316.
19. Dumas T.C., Foster T.C. Late developmental changes in the ability of adenosine A1 receptors to regulate synaptic transmission in the hippocampus. Developmental Brain Research 1998, 105:137-139.
20. Erwin R.J., Mawhinney-Hee M., Gur R.C., Gur R.E. Midlatency auditory evoked responses in schizophrenia. Biological Psychiatry 1991, 30:430-442.
21. Erwin R.J., Shtasel D., Gur R.E. Effects of medication history on midlatency auditory evoked responses in schizophrenia. Schizophrenia Research 1994, 11:251-258.
22. Erwin R.J., Turetsky B.I., Moberg P., Gur R.C., Gur R.E. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophrenia Research 1998, 33:157-167.
23. Ferre S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) 1997, 133:107-120.
24. First M.B. The DSM series and experience with DSM-IV. Psychopathology 2002, 35:67-71.
25. Freedman R., Adler L.E., Waldo M.C., Pachtman E., Franks R.D. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biological Psychiatry 1983, 18:537-551.
26. Freedman R., Waldo M., Bickford-Wimer P., Nagamoto H. Elementary neuronal dysfunctions in schizophrenia. Schizophrenia Research 1991, 4:233-243.
27. Ghisolfi E.S., Prokopiuk A.S., Becker J., Ehlers J.A., Belmonte-de-Abreu P., Souza D.O., Lara D.R. The adenosine antagonist theophylline impairs p50 auditory sensory gating in normal subjects. Neuropsychopharmacology 2002, 27:629-637.
28. Ghisolfi E.S., Schuch A., Strimitzer I.M., Luersen G., Martins F.F., Ramos F.L., Becker J., Lara D.R. Caffeine modulates P50 auditory sensory gating in healthy subjects. European Neuropsychopharmacology 2006, 16:204-210.
29. Hall M.H., Taylor G., Salisbury D.F., Levy D.L. Sensory gating event-related potentials and oscillations in schizophrenia patients and their unaffected relatives. Schizophrenia Bulletin 2011, 37:1187-1199.
30. Hershman K.M., Freedman R., Bickford P.C. GABAB antagonists diminish the inhibitory gating of auditory response in the rat hippocampus. Neuroscience Letter 1995, 190:133-136.
31. Hillion J., Canals M., Torvinen M., Casado V., Scott R., Terasmaa A., Hansson A., Watson S., Olah M.E., Mallol J., Canela E.I., Zoli M., Agnati L.F., Ibanez C.F., Lluis C., Franco R., Ferre S., Fuxe K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. Journal of Biological Chemistry 2002, 277:18091-18097.
32. Hong L.E., Summerfelt A., Mitchell B.D., McMahon R.P., Wonodi I., Buchanan R.W., Thaker G.K. Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Archives of General Psychiatry 2008, 65:1008-1016.
33. Hong X., Chan R.C., Zhuang X., Jiang T., Wan X., Wang J., Xiao B., Zhou H., Jiang L., Weng B. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophrenia Research 2009, 108:151-157.
34. Johansson B., Georgiev V., Lindstrom K., Fredholm B.B. A1 and A2A adenosine receptors and A1 mRNA in mouse brain: effect of long-term caffeine treatment. Brain Research 1997, 762:153-164.
35. Kurumaji A., Toru M. An increase in [3H] CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Research 1998, 808:320-323.
36. Lara D.R. Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit. Cellular and Molecular Neurobiology 2002, 22:239-247.
37. Lara D.R., Dall'Igna O.P., Ghisolfi E.S., Brunstein M.G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Progress in Neuro-Psychopharmacology &. Biological Psychiatry 2006, 30:617-629.
38. Lara D.R., Souza D.O. Schizophrenia: a purinergic hypothesis. Medical Hypotheses 2000, 54:157-166.
39. Lara D.R., Vianna M.R., de Paris F., Quevedo J., Oses J.P., Battastini A.M., Sarkis J.J., Souza D.O. Chronic treatment with clozapine, but not haloperidol, increases striatal ecto-5'-nucleotidase activity in rats. Neuropsychobiology 2001, 44:99-102.
40. Light G.A., Malaspina D., Geyer M.A., Luber B.M., Coleman E.A., Sackeim H.A., Braff D.L. Amphetamine disrupts P50 suppression in normal subjects. Biological Psychiatry 1999, 46:990-996.
41. Light G.A., Geyer M.A., Clementz B.A., Cadenhead K.S., Braff D.L. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. American Journal of Psychiatry 2000, 157:767-771.
42. Lucas P.B., Pickar D., Kelsoe J., Rapaport M., Pato C., Hommer D. Effects of the acute administration of caffeine in patients with schizophrenia. Biological Psychiatry 1990, 28:35-40.
43. Martini C., Tuscano D., Trincavelli M.L., Cerrai E., Bianchi M., Ciapparelli A., Alessio L., Novelli L., Catena M., Lucacchini A., Cassano G.B., Dell'Osso L. Upregulation of A2A adenosine receptors in platelets from patients affected by bipolar disorders under treatment with typical antipsychotics. Psychiatry Research 2006, 40:81-88.
44. Mayo K.M., Falkowski W., Jones C.A. Caffeine: use and effects in long-stay psychiatric patients. British Journal of Psychiatry 1993, 162:543-545.
45. McRedmond J.P., Park S.D., Reilly D.F., Coppinger J.A., Maguire P.B., Shields D.C., Fitzgerald D.J. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Molecular & Cellular Proteomics 2004, 3:133-144.
46. Mikkelsen E.J. Caffeine and schizophrenia. Journal of Clinical Psychiatry 1978, 39:732-736.
47. Mitchell J.B., Lupica C.R., Dunwiddie T.V. Activity-dependent release of endogenous adenosine modulates synaptic responses in the rat hippocampus. Journal of Neuroscience 1993, 13:3439-3447.
48. Nagamoto H.T., Adler L.E., Waldo M.C., Freedman R. Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biological Psychiatry 1989, 25:549-561.
49. Nagamoto H.T., Adler L.E., Waldo M.C., Griffith J., Freedman R. Gating of auditory response in schizophrenics and normal controls. Effects of recording site and stimulation interval on the P50 wave. Schizophrenia Research 1991, 4:31-40.
50. Nagel J., Schladebach H., Koch M., Schwienbacher I., Muller C.E., Hauber W. Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse 2003, 49:279-286.
51. Othman T., Yan H., Rivkees S.A. Oligodendrocytes express functional A1 adenosine receptors that stimulate cellular migration. Glia 2003, 44:166-172.
52. Parsons B., Togasaki D.M., Kassir S., Przedborski S. Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. Journal of Neurochemistry 1995, 65:2057-2064.
53. Patterson J.V., Hetrick W.P., Boutros N.N., Jin Y., Sandman C., Stern H., Potkin S., Bunney W.E. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Research 2008, 158:226-247.
54. Pinna A., Wardas J., Cozzolino A., Morelli M. Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol. Neuropsychopharmacology 1999, 20:44-51.
55. Rivkees S.A. The ontogeny of cardiac and neural A1 adenosine receptor expression in rats. Developmental Brain Research 1995, 89:202-213.
56. Rivkees S.A., Zhao Z., Porter G., Turner C. Influences of adenosine on the fetus and newborn. Molecular Genetics and Metabolism 2001, 74:160-171.
57. Sanchez-Morla E.M., Garcia-Jimenez M.A., Barabash A., Martinez-Vizcaino V., Mena J., Cabranes-Diaz J.A., Baca-Baldomero E., Santos J.L. P50 sensory gating deficit is a common marker of vulnerability to bipolar disorder and schizophrenia. Acta Psychiatrica Scandinavica 2008, 117:313-318.
58. Smith D.A., Boutros N.N., Schwarzkopf S.B. Reliability of P50 auditory event-related potential indices of sensory gating. Psychophysiology 1994, 31:495-502.
59. Soslau G., Giles J. The loss of sialic acid and its prevention in stored human platelets. Thrombosis Research 1982, 26:443-455.
60. Svenningsson P., Le Moine C., Fisone G., Fredholm B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Progress in Neurobiology 1999, 59:355-396.
61. Thaker G.K. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophrenia Bulletin 2008, 34:760-773.
62. Trincavelli M.L., Cuboni S., Catena Dell'osso M., Maggio R., Klotz K.N., Novi F., Panighini A., Daniele S., Martini C. Receptor crosstalk: haloperidol treatment enhances A(2A) adenosine receptor functioning in a transfected cell model. Purinergic Signal 2010, 6:373-381.
63. Trincavelli M.L., Daniele S., Ciapparelli A., Dell'Osso M.C., Massimetti G., Marazziti D., Dell'Osso L., Martini C. Changes in A2a adenosine receptor parameters in patients affected by bipolar disorders: correlation with antipsychotic dosage and severity of illness. Open Journal of Psychiatry 2012, 2:1-8.
64. Varani K., Portaluppi F., Merighi S., Ongini E., Belardinelli L., Borea P.A. Caffeine alters A2A adenosine receptors and their function in human platelets. Circulation 1999, 99:2499-2502.
65. Waldo M.C., Cawthra E., Adler L.E., Dubester S., Staunton M., Nagamoto H., Baker N., Madison A., Simon J., Scherzinger A., Drebinga C., Gerhardtb G., Freedman R. Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings. Schizophrenia Research 1994, 12:93-106.
66. Wang J.H., Short J., Ledent C., Lawrence A.J., van den Buuse M. Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behavioural Brain Research 2003, 143:201-207.
67. Wilson C.L., Babb T.L., Halgren E., Wang M.L., Crandall P.H. Habituation of human limbic neuronal response to sensory stimulation. Experimental Neurology 1984, 84:74-97.
68. Wood C.C., Allison T., Goff W.R., Williamson P.D., Spencer D.D. On the neural origin of P300 in man. Progress in Brain Research 1980, 54:51-56.